BioSpace News Archive

CyberMDX, a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced it has joined the Microsoft Intelligent Security Association (MISA),

OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, announced its Rheumatoid Arthritis (RA) registry now includes longitudinal clinical data from rheumatology specialists on more than 200,000 patients

SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced that dosing has commenced in the company’s Phase 1, dose-escalation study of ST-2427, a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain.

Ora, Inc., the world’s leading partner for ophthalmic pharmaceutical and device development, announced today that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role: Chief Development Officer (CDO).

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma.

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, called the Aura CL.

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for B-Capta®, the new in-line, blood-gas monitoring system integrated into the market-leading S5® heart-lung machine (HLM)

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (“FDA”) supporting the Company’s development strategy to submit an initial new drug application (“IND”) application for a Phase 2 study of Trappsol

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit

We are proud to share that the unaudited number of tests processed by the ScreenPro team for the month of March were over 30,000.